Herpes simplex virus glycoprotein D-specific T-cell receptor–peptide–major histocompatibility complex (HSV gD TCR–pMHC)

The Herpes simplex virus (HSV) glycoprotein D (gD)-specific T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) is a critical molecular assembly involved in the cellular immune response against HSV-1 and HSV-2. Glycoprotein D is a key viral entry protein and a dominant target for both neutralizing antibodies and T-cell responses. The complex forms when an HSV-infected cell or antigen-presenting cell processes gD into peptides and presents them on MHC molecules (typically Class II for CD4+ T-cells, such as HLA-DRB1*01:01), which are then recognized by specific T-cell receptors. This interaction is the fundamental trigger for T-cell activation, proliferation, and the subsequent release of antiviral cytokines like interferon-gamma. In therapeutic development, this complex is targeted through subunit vaccines designed to elicit gD-specific T-cells or through advanced TCR-engineered T-cell therapies (TCR-T) that aim to provide patients with a pre-existing population of T-cells capable of recognizing and eliminating HSV-infected reservoirs. Understanding the structural biology of this complex is essential for overcoming viral immune evasion and improving the efficacy of immunotherapies for chronic herpes infections.

Other names

HSV gD TCR-pMHC complexHerpes simplex virus gD-specific TCR-peptide-MHCHSV-2 gD(245-259)-HLA-DRB1*01:01 complexGlycoprotein D-specific T-cell receptor complex

The complex serves as the primary recognition unit for the adaptive immune system; drugs or therapies target this by either providing the antigen (vaccines) to form the complex and prime T-cells, or by engineering T-cells with specific TCRs to recognize the pMHC on infected cells, leading to targeted lysis of HSV-infected cells.